Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Van Cutsem E, et al. Among authors: nippgen j. N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019. N Engl J Med. 2009. PMID: 19339720 Free article. Clinical Trial.
Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Hakenberg OW, Perez-Gracia JL, Castellano D, Demkow T, Ali T, Caffo O, Heidenreich A, Schultze-Seemann W, Sautois B, Pavlik I, Qin A, Novosiadly RD, Shahir A, Ilaria R Jr, Nippgen J. Hakenberg OW, et al. Among authors: nippgen j. Eur J Cancer. 2019 Jan;107:186-195. doi: 10.1016/j.ejca.2018.10.005. Epub 2018 Dec 17. Eur J Cancer. 2019. PMID: 30573277 Clinical Trial.
A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.
Wagner AJ, Kindler H, Gelderblom H, Schöffski P, Bauer S, Hohenberger P, Kopp HG, Lopez-Martin JA, Peeters M, Reichardt P, Qin A, Nippgen J, Ilaria RL, Rutkowski P. Wagner AJ, et al. Among authors: nippgen j. Ann Oncol. 2017 Mar 1;28(3):541-546. doi: 10.1093/annonc/mdw659. Ann Oncol. 2017. PMID: 28426120 Free PMC article. Clinical Trial.
A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors.
Chiorean EG, Sweeney C, Youssoufian H, Qin A, Dontabhaktuni A, Loizos N, Nippgen J, Amato R. Chiorean EG, et al. Among authors: nippgen j. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604. doi: 10.1007/s00280-014-2389-9. Epub 2014 Jan 23. Cancer Chemother Pharmacol. 2014. PMID: 24452395 Clinical Trial.
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.
Friess H, Langrehr JM, Oettle H, Raedle J, Niedergethmann M, Dittrich C, Hossfeld DK, Stöger H, Neyns B, Herzog P, Piedbois P, Dobrowolski F, Scheithauer W, Hawkins R, Katz F, Balcke P, Vermorken J, van Belle S, Davidson N, Esteve AA, Castellano D, Kleeff J, Tempia-Caliera AA, Kovar A, Nippgen J. Friess H, et al. Among authors: nippgen j. BMC Cancer. 2006 Dec 11;6:285. doi: 10.1186/1471-2407-6-285. BMC Cancer. 2006. PMID: 17156477 Free PMC article. Clinical Trial.
Expression of Ki-67 in squamous cell carcinoma of the penis.
Berdjis N, Meye A, Nippgen J, Dittert D, Hakenberg O, Baretton GB, Wirth MP. Berdjis N, et al. Among authors: nippgen j. BJU Int. 2005 Jul;96(1):146-8. doi: 10.1111/j.1464-410X.2005.05584.x. BJU Int. 2005. PMID: 15963138
15 results